Biotechnology company Compass Pathways plc (Nasdaq: CMPS) announced on Wednesday that it has completed recruitment for its Phase 3 COMP005 trial investigating COMP360 psilocybin in treatment-resistant depression (TRD). Screening is now closed, with final participants undergoing pre-dosing procedures.
Top-line results for the trial's 6-week primary endpoint remain on track for late Q2 2025, with 26-week data expected following the completion of the COMP006 trial in the second half of 2026.
COMP360 is a synthetic psilocybin formulation designed for use with psychological support. The trial is the largest randomized, controlled, double-blind psilocybin study ever conducted.
Compass Pathways is focused on accelerating access to evidence-based innovations in mental health. COMP360 has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for TRD.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval